Fig. 7: Inhibiting RhoA activity improves function of aged HSCs.

a, Experimental strategy for transplantation of young, aged and aged + Ri RFP⁺ HSCs into NBSGW mice. b, Percentage of engraftment in peripheral blood along the course of the transplantation at 6, 12 and 18 weeks. Four independent transplantation experiments were performed, and the initial number of recipient mice used per experiment was 3−4 per group. Young n = 9, aged n = 10, aged+Ri n = 10. Mann−Whitney test, unpaired, two-tailed, *P < 0.05, **P < 0.01, ***P < 0.001. c, Representative flow cytometry gating strategies for RFP⁺ cells, lymphoid cells (CD3⁺ and B220⁺) and myeloid cells (Gr1⁺, Gr1⁺Mac1⁺ and Mac1⁺) in peripheral blood at 18 weeks. d, Graphs showing the percentage of donor-derived B220⁺ cells, myeloid (Gr1⁺, Gr1⁺Mac1⁺ and Mac1⁺ cells) and CD3⁺ cells in peripheral blood at 6, 12 and 18 weeks after transplantation. Young n = 9, aged n = 10, aged+Ri n = 10. Graphs show mean ± s.e.m., Mann−Whitney test, unpaired, two-tailed, *P < 0.05, ***P < 0.001; only P < 0.05 (significant) values are shown. e, Cartoon scheme summarizing the main features rejuvenated by Ri treatment in aged HSCs. Panel a and e created with BioRender.